Translational ADMET for Drug Therapy: Principles, Methods, and Pharmaceutical Applications

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) are among the most critical factors that affect pharmacological response and drug safety. Preclinical and clinical tools can improve drug design and make the process of drug candidate selection more effective. The correlation between in vitro, in vivo, and in silico can further translate the data across a species and bring forth new approaches that reveal adverse side effects, adverse reactions, drug–drug interactions, and mechanisms of drug disposition.

To address this critical aspect of drug development, Translational ADMET for Drug Therapy presents effective technologies, methods, applications, data interpretation, and decision–making tactics for pharmaceutical and preclinical scientists. Chapters cover case studies and in vivo, in vitro, and in silico tools for optimal drug design, with new translational approaches to drug development and investigation.

Compiling the most effective approaches and technologies used to investigate ADMET and PKPD, this book offers a number of key benefits that include:

          Illustration of ADME properties from bedside to bench and bench to bedside, for the design of safe and effective medicine in human populations

          Examples that demonstrate the integration of in vitro, in vivo, and in silico data to address human PKPD and TKTD and help determine the proper therapeutic dosage

          Discussion of successful tools for evaluating drugs and covers current translational ADMET with regulatory guidelines

          A hands–on manual for researchers and scientists to design and execute in vitro, in silico, preclinical, and clinical studies

Souzan Yanni, PhD, is Founder and President of DMPK Consultants, Inc., which leads ADME/PK in support of preclinical and clinical investigations for of pharmaceutical and biotech companies.  She has over 20 years of hands–on leadership experience in planning, executing, and overseeing drug discovery and early development for therapeutic programs with national and international pharmaceutical companies, biotech groups, and CROs. Dr. Yanni possesses a PhD in Pharmaceutical Sciences, MS in Biochemistry, and BS in Chemistry. She is the author of several peer–reviewed articles, review articles, and book chapters on ADMET/PK as well as an external reviewer / editor for other journals.